U.S. Markets closed

How Novartis’s Sandoz Performed in the Third Quarter

Mike Benson
How Novartis’s Sandoz Performed in the Third Quarter

Novartis’s (NVS) Sandoz is a market leader in differentiated generics. Sandoz reported a 6% decrease in its YoY revenues to ~$2.42 billion during the third quarter of 2018 as compared to $2.58 billion during the third quarter of 2017. The decrease includes a 4% decrease in operating revenues and a 2% negative impact of foreign exchange during the quarter.